The Company of Biologists

Table 2.

gli2 MO injections into yot^–/+× yot^–/+crosses^*

gli2 MO injected	yot^-/- phenotype(^[UNK]nk2.2, nomyoD)	yot^-/+ phenotype (wt nk2.2,^[UNK]myoD)	Wild-type (nk2.2, myoD)	Total
Uninjected siblings^*	62 (23%)	141 (51%)	73 (26%)	276
1 ng	3 (5%)	15 (24%)	45 (71%)	63
3-7 ng	0	18 (23%)	61 (77%)	79
10-15 ng	0	25 (14%)	148 (86%)	173
	nk2.1b reduced in di.	Partial nk2.1b rescue	wt nk2.1b
Uninjected	26 (30%)	0	60 (70%)	86
6 ng	0	8 (21%)	30 (79%)	38^**
10 ng	0	1 (2%)	39 (98%)	40^**

gli2 MO injected	yot^-/- phenotype(^[UNK]nk2.2, nomyoD)	yot^-/+ phenotype (wt nk2.2,^[UNK]myoD)	Wild-type (nk2.2, myoD)	Total
Uninjected siblings^*	62 (23%)	141 (51%)	73 (26%)	276
1 ng	3 (5%)	15 (24%)	45 (71%)	63
3-7 ng	0	18 (23%)	61 (77%)	79
10-15 ng	0	25 (14%)	148 (86%)	173
	nk2.1b reduced in di.	Partial nk2.1b rescue	wt nk2.1b
Uninjected	26 (30%)	0	60 (70%)	86
6 ng	0	8 (21%)	30 (79%)	38^**
10 ng	0	1 (2%)	39 (98%)	40^**

: reduced; di: diencephalon.

Expected genotypes: 25% yot^-/-, 50%yot^-/+, 25% homozygous wild type.

All gli2 MO-injected embryos showed expanded nk2.1b in the telencephalon.